<DOC>
	<DOCNO>NCT00937157</DOCNO>
	<brief_summary>This study : - Explore whether GA decrease inflammation 3T optimize protocol compare 1.5T standard protocol . - Compare whether decrease cumulative number Gd-enhancing lesion significantly differs pre-treatment ( day 0 ) post-treatment ( 12 month ) use 1.5T standard 3T optimized protocol . - Investigate correlation MTR cumulative number volume Gd enhance lesion 1.5T standard 3T optimized protocol patient treat GA . This study suggest GA may favorably affect early event lesion formation , addition exert transient beneficial effect establish area inflammation demyelination , effect may observe 3T optimize protocol .</brief_summary>
	<brief_title>Comparison 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate ( GA )</brief_title>
	<detailed_description>Interferon-β ( IFN- β ) glatiramer acetate ( GA ) two main group drug use treatment multiple sclerosis ( MS ) . Notably , ultimately decrease central nervous system ( CNS ) inflammation , different mechanism . Therefore , use 1.5T MRI , triple dose Gd , delay scan time 20-30 min Gd injection , application off-resonance saturate MT pulse may increase ability detect Gd lesion approximately 120 % compare 1.5T single dose MRI protocol . The 3T standard protocol may increase ability detect Gd enhance lesion 40-50 % compare 1.5T standard protocol . This may indicate 3T optimize protocol may increase ability Gd lesion detection approximately 150-180 % , compare 1.5T standard protocol .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Patients diagnose clinically definite MS accord McDonald criterion Have Gd enhance lesion use 1.5T standard protocol and/or acute relapse Age 1865 Have relapsingremitting ( RR ) disease course clinically isolated syndrome ( CIS ) high risk conversion clinically definite ( CD ) MS ( presence &gt; 9 T2 lesion addition 1 Gd lesion ) Have EDSS score less equal 5.5 Have disease duration 3 month 30 year None exclusion criterion Previous immunomodulatory immunosuppressant treatment 30 day prior day 0 study follow agent ( e.g. , IFNβ , GA , mitoxantrone , cyclophosphamide , cladribine , fludarabine , cyclosporine , total body , azathioprine , methotrexate , IVIG , cellcept , natalizumab , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Glatiramer Acetate</keyword>
	<keyword>Gd enhance lesion</keyword>
	<keyword>1.5T protocol</keyword>
	<keyword>3T protocol</keyword>
	<keyword>Magnetization transfer imaging ( MTI )</keyword>
	<keyword>Lesion activity analysis</keyword>
	<keyword>Copaxone</keyword>
</DOC>